0000000000995583

AUTHOR

L. Preotescu

showing 3 related works from this author

Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a…

2020

Background Accurate and up-to-date assessment of demographic metrics is crucial for understanding a wide range of social, economic, and public health issues that affect populations worldwide. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 produced updated and comprehensive demographic assessments of the key indicators of fertility, mortality, migration, and population for 204 countries and territories and selected subnational locations from 1950 to 2019. Methods 8078 country-years of vital registration and sample registration data, 938 surveys, 349 censuses, and 238 other sources were identified and used to estimate age-specific fertility. Spatiotemporal Gaussian…

Malevery elderlyDemographic transitionHALE030204 cardiovascular system & hematologypreschool childGlobal Burden of DiseaseCarga Global de Enfermedades0302 clinical medicinenewbornRisk FactorsSurveys and Questionnairesand Risk Factors Study80 and over030212 general & internal medicineBirth RateChildMigration11 Medical and Health SciencesAged 80 and overeducation.field_of_studyInjuriesGeographyMortality rate1. No povertyDEATHCensusesGeneral MedicineSDG 10 - Reduced InequalitiesMiddle AgedDemographic analysis3142 Public health care science environmental and occupational health3. Good healthdemographic analysisEstilo de Vida SaludableGeographyrisk factorChild Preschool/dk/atira/pure/sustainabledevelopmentgoals/reduced_inequalitiesDemography/statistics & numerical dataGlobal Burden of Diseases Injuries Risk Factors Fertility Mortality Migration Population/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingepidemiologyFemaleA990 Medicine and Dentistry not elsewhere classifiedCHILD-MORTALITYLive BirthGlobal Health MetricsTRANSITIONdemographics ; GBD ; fertility ; mortality ; haleAdultAdolescentTotal fertility ratePopulationPopulation.Global Burden of Diseases Injuries and Risk Factors StudyBirth rate03 medical and health sciencesYoung AdultLife ExpectancySDG 3 - Good Health and Well-beingGeneral & Internal MedicineSYSTEMATIC ANALYSISDemografíaHumansGlobal Burden of Disease StudyhumanMortalityeducationPreschoolAgedDemographySpatial AnalysisquestionnaireInfant NewbornKlinisk medicinHIVInfantGlobal Burden of Diseasessex-specific fertilityMortality rateLive Birth/epidemiology//purl.org/pe-repo/ocde/ford#3.02.00 [https].Global Burden of DiseasesMODELFertilidadFertilityDemographic changeLife expectancyNAglobal disease burdenClinical Medicinepopulation researchDemographyThe Lancet
researchProduct

Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-alpha and -delta, Induces Resolution of Nonalcoholic Steatohepatitis Withou…

2016

International audience; BACKGROUND & AIMS: Elafibranor is an agonist of the peroxisome proliferator-activated receptor-α and peroxisome proliferator-activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH).METHODS: Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and …

0301 basic medicineLiver CirrhosisMaleTime FactorsIntention to Treat Analysi[SDV]Life Sciences [q-bio]BiopsyPLACEBO-CONTROLLED TRIALTHERAPYGastroenterologySeverity of Illness IndexChalcone0302 clinical medicineChalconesNon-alcoholic Fatty Liver DiseaseGastrointestinal AgentNonalcoholic fatty liver diseasePropionateMedicine and Health SciencesOdds RatioMedicineGlucose homeostasisVITAMIN-Eeducation.field_of_studyGastrointestinal agentFatty liverRemission InductionGastroenterologyMiddle Aged3. Good healthIntention to Treat AnalysisPPARDEuropeTreatment OutcomeLiverACIDPIOGLITAZONE030211 gastroenterology & hepatologyFemalePPARAHumanSignal TransductionAdultCLINICAL-OUTCOMESmedicine.medical_specialtyLogistic ModelTime FactorLiver CirrhosiPopulationfatty liver; NAFLD; PPARA; PPARD; Adult; Biomarkers; Biopsy; Chalcones; Double-Blind Method; Europe; Female; Gastrointestinal Agents; Humans; Intention to Treat Analysis; Liver; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Odds Ratio; PPAR alpha; PPAR gamma; Propionates; Remission Induction; Severity of Illness Index; Signal Transduction; Time Factors; Treatment Outcome; United States; GastroenterologyPlacebo03 medical and health sciencesDouble-Blind MethodGastrointestinal AgentsInternal medicineNAFLDHumansPPAR alphaeducationFATTY LIVER-DISEASEfatty liverHepatologybusiness.industryBiomarkerAMERICAN ASSOCIATIONOdds ratiomedicine.diseaseConfidence intervalUnited StatesPPAR gammaRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]030104 developmental biologyEndocrinologyLogistic ModelsHuman medicinePropionatesbusinessBiomarkers
researchProduct

Five insights from the Global Burden of Disease Study 2019

2020

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD …

health care deliveryMaleHumans -- MalatiesOutcome Assessmentglobal healthDiseaseReviewinsights030204 cardiovascular system & hematologySocioeconomic FactorgeographyGlobal Burden of DiseaseNoncommunicable Diseasedisease burdenCarga Global de Enfermedades0302 clinical medicineRisk FactorsOutcome Assessment Health CareHealth careGlobal healthDelivery of health carehealth outcomesmiddle income countrybirth rate030212 general & internal medicineBirth Ratehealth outcomes health system responses economic developmentFactores de Riesgopublic healthhealth care costGeneral MedicineRisk factor (computing)humanities3. Good healthfemalepriority journalrisk factorhealth system responsesepidemiologyTERRITORIESpoliticsCLINICAL-TRIALSmedicine.medical_specialtyBirth Rate; Delivery of Health Care; Global Burden of Disease; Noncommunicable Diseases; Outcome Assessment Health Care; Risk Factors; Socioeconomic Factors; Wounds and Injuries; epidemiologyinjury2019195 COUNTRIESArticleGlobal Burden of Diseases health outcomes risk factors health system responsesHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]03 medical and health sciencessocioeconomicsmedicineSYSTEMATIC ANALYSISHumansGlobal Burden of Disease StudyhumanEpidemiologiaNoncommunicable DiseasesDisease burdenActuarial sciencehigh income countrybusiness.industryRisk FactorWounds and InjuriePublic healthagingHealth careeconomicsNon-communicable diseasemedicine.diseaseSalut públicaeconomic developmentEnfermedadesnon communicable disease//purl.org/pe-repo/ocde/ford#3.02.00 [https]Health CareRisk factorsSocioeconomic Factorspopulation growthLife expectancylife expectancyWounds and InjuriesNAPrestación de Atención de Saludglobal disease burdenbusinessDelivery of Health Carelow income country
researchProduct